AMG 876

Drug Profile

AMG 876

Alternative Names: AMG-876

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Antihyperglycaemics; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 09 Jun 2017 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Type 2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 29 Aug 2014 Amgen terminates a phase I trial in Type-2 diabetes mellitus in USA (NCT01856881)
  • 01 Mar 2013 Amgen initiates enrolment in a phase I trial for Type-2 diabetes mellitus in USA (NCT01856881)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top